Hepatology International

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	173
Platelets in acute liver failure: an innocent bystander or instigator?	149
Metabolically healthy obese and MAFLD: does weight status alone matter?	88
Beyond left versus right: from puncture site selection to clinical strategy in TIPS	83
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	65
Clinical trial endpoints for metabolic dysfunction and alcohol associated steatotic liver disease	62
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	61
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	60
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	59
Precision medicine for G-CSF in ACLF: the biomarker gap	58
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	54
Comment on “Diabetes mellitus is linked to higher mortality in alcohol‑related acute‑on‑chronic liver failure”	51
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	51
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	50
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	49
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	46
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	45
Noninvasive risk stratification of liver nodule development in Fontan-associated liver disease using liver stiffness measurement	45
Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation	45
Comment on “Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study”	44
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	44
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	43
Comment on “Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon”	43
Letter to the Editor: Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study	43
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	43

Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	42
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	41
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	40
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	40
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	40
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	39
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	39
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	39
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	38
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	38
Reply to: “developing real‑world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond”	37
Letter to the editor: Treating portal vein thrombosis in cirrhosis: is anticoagulation therapy overestimated?	35
Targeting immuno-metabolism and anti-viral immune responses in chronic hepatitis B	35
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures	34
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study	34
Identifying the early predictors of non-response to steroids in patients with flare of autoimmune hepatitis causing acute-on-chronic liver failure	33
Novel and simplified model for the precise identification of concurrent bacterial infections in patients aged 60 years and older with acute-on-chronic liver diseases: a nationwide, multicentre, prospe	33
A combined model of HBcrAg, anti-HBc, and anti-HBs predicts recurrence after functional cure of chronic hepatitis B	32
Regarding the methodological aspects of the TabPFN model for predicting post-TIPS hepatic encephalopathy	31
Methodological considerations in linking depression to metabolic dysfunction-associated steatotic liver disease: insights for future study design	30
The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease	30
Comments on “Three‑year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab”	30
The relationship between CXCR6+CD8+T cells and clinicopathological parameters in patients with primary biliary cholangitis	30
Refining the definition of acute autoimmune hepatitis: implications for classification and prognosis	30
Prospects for treatment of esophageal varices considering the safety of endoscopic band ligation	30
Metabolic dysfunction-associated steatotic liver disease increases the incidence of metachronous liver metastases from TNM stage 0–II colorectal cancer	29
Gut microbes associated with functional cure of chronic hepatitis B	29
Prevalence and impact on the outcome of myosteatosis in patients with cirrhosis: a systematic review and meta-analysis	28
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan	28
Metabolic dysfunction associated fatty liver disease in healthy weight individuals	27
Enhancing the understanding and management of metabolic dysfunction-associated steatotic liver disease in colorectal cancer patients: insights and future directions	27
Role of splenic hepatic elastography ratio in differentiating non-cirrhotic portal fibrosis and chronic liver disease in children and adolescents	27
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients	27
Liver-derived extracellular vesicles from patients with hepatitis B virus-related acute-on-chronic liver failure impair hepatic regeneration by inhibiting on FGFR2 signaling via miR-218-5p	27
Correction to: Targeting ferroptosis in hepatocellular carcinoma	27
The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study	26
Anti-PD-L1 antibodies promote cellular proliferation by activating the PD-L1–AXL signal relay in liver cancer cells	26
APASL STC 2025, Istanbul	26
Native liver survival with therapeutic plasma exchange in acutely decompensated hepatic Wilson Disease: revisiting the Dhawan index	26
Comment on “BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression”	25
Reply to letter to editor “Hepatic irAEs, ICI Continuation, and Survival: Methodological Perspectives and Future Directions”	25
Fecal microbiota transplantation in alcoholic hepatitis: new treatment paradigm or a shot in the dark?	25
Correction: The interplay between lymphatic system and portal hypertension: a comprehensive review	25
MAFLD, patient-centred care, and APASL	25
Downregulated VISTA enhances Th17 differentiation and aggravates inflammation in patients with acute-on-chronic liver failure	25
Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study	24
Stage-specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma	24
GLP-1 receptor agonists in metabolic dysfunction-associated steatohepatitis: a systematic review and meta-analysis of randomized controlled trials	23
Immune biomarkers predicting response to G-CSF in acute-on-chronic liver failure: results from a GRAFT trial sub-study	23
Liver decompensation: the yard stick that measures indications and adverse effects of human albumin infusion	23

Prevalence and associated factors of metabolic dysfunction-associated steatotic liver disease in Taiwan, 2001–2021	23
Global prevalence, metabolic characteristics, and outcomes of lean-MAFLD: a systematic review and meta-analysis	23
Correction: Liver transplantation for acute-on-chronic liver failure	23
The association between visceral adipocyte hypertrophy and NAFLD in subjects with different degrees of adiposity	22
The effect of transition timing of regorafenib on treatment outcomes in unresectable hepatocellular carcinoma: a real-world study	22
Comment on: Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment	22
Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?	22
Australian best practice recommendations for transjugular intrahepatic portosystemic shunt (TIPS) in portal hypertension: a consensus statement	22
Correction to: Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	22
Distinctly altered lipid components in hepatocellular carcinoma relate to impaired T cell-dependent antitumor immunity	22
Comment on ‘Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)’	22
ChIP-seq analysis found IL21R, a target gene of GTF2I–the susceptibility gene for primary biliary cholangitis in Chinese Han	22
Distinct course of portal hypertension in patients with cirrhosis with gastric variceal bleeding as their first decompensation: a propensity score-matched study	21
A somatic mutation-derived LncRNA signatures of genomic instability predicts the prognosis and tumor microenvironment immune characters in hepatocellular carcinoma	21
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals	20
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD	20
Temporal trends and regional variations in hepatocellular carcinoma etiology: a multinational study across Asia	20
Enhancing the prognostic value of inflammatory markers in hepatocellular carcinoma: a thoughtful discussion	20
AGEX: a comprehensive database of clinically relevant genetic variants associated with Alagille syndrome across diverse populations	20
Sleep patterns, genetic susceptibility, and risk of cirrhosis among individuals with nonalcoholic fatty liver disease	20
Diagnostic yield and novel candidate genes by next generation sequencing in 166 children with intrahepatic cholestasis	20
Genetic predisposition of metabolic dysfunction-associated steatotic liver disease: a population-based genome-wide association study	19
From comorbidity to catalyst: mechanistic and therapeutic implications of diabetes mellitus in alcohol-related acute-on-chronic liver failure	19
Skeletal muscle alterations indicate poor prognosis in cirrhotic patients: a multicenter cohort study in China	19
Reduction of natural killer cells is associated with poor outcomes in patients with hepatitis B virus-related acute-on-chronic liver failure	19
Gender differences in non-alcoholic fatty liver disease in obese children and adolescents: a large cross-sectional study	19
Gout is independently associated with occult hepatic fibro-inflammation independent of obesity: a multi-cohort study using MRI-cT1 and elastography	19
Comments on: CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma	19
AARC score and urine NGAL predict terlipressin non-response and mortality in patients with acute-on-chronic liver failure	19
Interferon therapy improves survival in patients with hepatitis B virus-related hepatocellular carcinoma after curative surgery: a meta-analysis	18
Integrated genomic analyses of hepatocellular carcinoma	18
The effectiveness of combination therapy with interferon and nucleoside analogs in pediatric patients with chronic hepatitis B: a systematic review and meta-analysis	18
Explainable attention-enhanced heuristic paradigm for multi-view prognostic risk score development in hepatocellular carcinoma	18
Comment on “Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes”	18
Diet-derived antioxidants and nonalcoholic fatty liver disease: a Mendelian randomization study	18
APASL STC on Alcohol Associated Liver Disease: Moscow 2025	18
Impact of metabolic factors on risk of cardiovascular disease in nondiabetic metabolic dysfunction-associated fatty liver disease	18
Stem cells therapies for liver diseases: for current practice and future goals	18
CBX1 is involved in hepatocellular carcinoma progression and resistance to sorafenib and lenvatinib via IGF-1R/AKT/SNAIL signaling pathway	18
Diversity of the nucleic acid forms of circulating HBV in chronically infected patients and its impact on viral cycle	17
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study	17
PIVKA-II combined with alpha-fetoprotein for the diagnostic value of hepatic tumors in children: a multicenter, prospective observational study	17
Correction to: Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells	17
Reconsiderations for the liver donation from a living donor: addressing hepatic steatosis with weight loss preconditioning	17
PIRO-CIC model can predict mortality and futility of care in critically ill cirrhosis patients in the intensive care unit	17
Commentary on “Predictive value of soluble PD-1 for HBsAg loss in HBeAg-negative chronic hepatitis B patients: a prospective study”	17
Oxidative stress triggers hyperdynamic circulation via central neural activation in portal hypertensive rats	17
New progress towards elimination of mother-to-child transmission of hepatitis B virus in China	17
Metabolic implications of tenofovir alafenamide in chronic hepatitis B: a commentary on cardiovascular and lipid risks	16
Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis	16
Towards precise evaluation of steatotic liver disease subtypes and adverse pregnancy outcomes: methodological insights	16
Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations	16
Hepatitis B virus-related intrahepatic cholangiocarcinoma originates from hepatocytes	16
Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma	16
Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective	16
Advancing personalized risk assessment in post-TIPS hepatic encephalopathy: insights and future directions	16
The clinical implications and molecular features of intrahepatic cholangiocarcinoma with perineural invasion	16
Diagnosis and management of pediatric acute liver failure: consensus recommendations of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)	16
Editorial: The safety profile of endoscopic variceal ligation in patients with esophageal varices. Authors’ reply	16
Nomograms should be noted	16
Effect of testosterone addition to nutrition and exercise on muscle mass in men with cirrhosis: the next trial	15
Reply to Letter to the Editor “Hepatic irAE, ICI continuation, and survival: need for robust evidence beyond initial observations”	15
Response to letters to editor "Next-Step Paradigms for Hepatitis B Functional Cure: Insights from the Anchor Combination Therapy Trial" and “Critical Appraisal of the Anchor RCT on Entecavir, Peginter	15
Bridging expression profiles and clinical outcomes in HCC target selection	15
Influence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	15
Predictive power of portal pressure gradient remeasured shortly after transjugular intrahepatic portosystemic shunt	15
Gut-microbiome composition and function in progression of alcohol-associated liver disease: going beyond western experiences	15
Global burden of cirrhosis and liver cancer due to alcohol: the past, present, and the future	15
The upregulation of Annexin A2 by TLR4 pathway facilitates lipid accumulation and liver injury via blocking AMPK/mTOR-mediated autophagy flux during the development of non-alcoholic fatty liver diseas	14
Characteristics of microbiome-derived metabolomics according to the progression of alcoholic liver disease	14
Circulating cfDNA CD86 methylation is associated with durable response to atezolizumab–bevacizumab in hepatocellular carcinoma	14
Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019	14
Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection	14
Comment on “Cirrhotic cardiomyopathy in children with biliary atresia and genetic intrahepatic cholestasis: clinical course and outcomes”	14
Comparison of the prognostic models for mortality in idiosyncratic drug-induced liver injury	14
Correction to: Infuence of shunt occlusion on liver volume and functions in hyperammonemic cirrhosis patients having large porto-systemic shunts: a randomized control trial	14
Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment	14
Clinical practice guidelines on hemochromatosis: Asian Pacific Association for the Study of the Liver	14
Comments on: Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis	14
FXR overexpression promotes liver regeneration through inducing FGF2 activation in APAP-induced acute liver injury	14

Insights in a prospective investigation of cardiomyopathy in children with biliary atresia and hereditary intrahepatic cholestasis: focus on diagnosis, survival analysis, and bias control	14
Methylated SEPT9 assay-based liquid biopsy as a biomarker in molecular targeted agent-treated hepatocellular carcinoma	14
Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort	14
Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon	14
Refining meta-analyses in advanced biliary tract cancer	14
Correction to: Complementary role of peripheral and central autonomic nervous system on insulin-like growth factor-1 activation to prevent fatty liver disease	14
Comment on “Efficacy and safety of atezolizumab and bevacizumab with or without TACE as first-line therapy for unresectable HCC: a multicenter cohort study”	14
Exosomal miR-200b-3p induce macrophage polarization by regulating transcriptional repressor ZEB1 in hepatocellular carcinoma	13
Multi-omics analysis of the lactylation-driven microenvironment and non-invasive clinical translation in hepatocellular carcinoma	13
BRIX1 activated by mTORC1-SP1 signaling regulates ribosome biogenesis and alternative splicing to promote hepatocellular carcinoma progression	13
Tolvaptan for hyponatremia in patients with cirrhosis: a post hoc subgroup analysis of a multicenter, randomized, double-blind, placebo-controlled trial	13
Spatial analysis identifies LAMTOR2 overexpression in hepatocellular carcinoma with vessels encapsulating tumor clusters	13
Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes	13
Epidemiological characteristics in Shanghai and a prognostic nomogram for 90 day adverse outcomes in acute hepatitis E	13
How non-alcoholic fatty liver disease and cirrhosis affect the heart	13
Characteristics and long-term mortality of patients with non-MAFLD hepatic steatosis	13
Safety, pharmacokinetics and antiviral activity of AHB‑137 in healthy volunteers and chronic hepatitis B patients: a phase 1a/1b study	13
Expanding treatment indications in chronic hepatitis B: Should we treat all patients?	13
Comment on “Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation”	13
Whole-exome sequencing reveals the metastatic potential of hepatocellular carcinoma from the perspective of tumor and circulating tumor DNA	13
Response to Letter to Editor: “Systemic inflammation and prognosis in HCC: a closer look”	13
Developing real-world prognostic models for patients with advanced hepatocellular carcinoma: CRAFITY, mALF and beyond	13
Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people	12
Autophagy and extracellular vesicles in the liver endothelium: friends or foes?	12
Liver fibrosis is associated with impaired bone mineralization and microstructure in obese individuals with non-alcoholic fatty liver disease	12
A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper	12
Safety of right liver donation after improving steatosis through weight loss in living donors: a retrospective study	12
Methodological and safety considerations for combination immunotherapy and NA cessation in CHB	12
Synthetic miR-26a mimics delivered by tumor exosomes repress hepatocellular carcinoma through downregulating lymphoid enhancer factor 1	12
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024	12
Re-examining the incremental benefit of TACE–TKI–PD-1 triplet therapy: time-related bias and treatment pathways in a real-world HCC cohort	12
Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled trial	12
The incidence of spontaneous HBsAg loss in patients with different baseline HBsAg levels: a systematic review and meta-analysis	12
Response to letter—Machine learning prediction of rapid HBsAg seroclearance at week 24 in inactive carriers treated with pegylated interferon	12